Molecular insights firm Predicine has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its SARS-CoV-2 RT-PCR test and self-collection kit.

The latest move will allow the company to expand its Covid-19 testing capability across the country to a broad community population.

The SARS-CoV-2 RT-PCR Test is designed to detect nucleic acid in anterior nasal samples that are collected from individuals with or without Covid-19 symptoms.

It is a DNA extraction-free process with matrix sample collection tubes that provide accurate results in less than six hours from receiving a sample.

With sample self-collection, the company will be able to expand its mass testing for Covid-19.

The test kit has also been developed to use anterior nasal swab samples self-collected at home under adult supervision for those aged 14 years and above, and collected with the assistance of adults for individuals aged two years and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Predicine founder and CEO Shidong Jia said: “Obtaining FDA EUA approval for Predicine’s Covid-19 PCR test and at-home collection kit is a significant milestone that aligns with Predicine’s strategic focus to execute new product development in oncology and infectious disease.

“This approval is timely during another Covid-19 surge nationwide. This furthers the national effort to control the spread of the virus and protect the community and general public.”

The company stated that it has five CLIA-certified laboratories across the US, which include two in Silicon Valley, as well as new labs in Los Angeles, Houston and Chicago.

It is currently working with public health networks and private entities to provide increased access to Covid-19 testing.

The latest regulatory approval supports the company’s efforts to provide accessible and affordable molecular testing solutions for infectious diseases and oncology.